CSF-IAP levels increased significantly in patients with multiple sclerosis (MS) during both the active and inactive stages and in patients with Guillain-Barr? syndrome (GBS) or Miller Fisher syndrome (MFS) as compared with those of control patients, but not in patients with amyotrophic lateral sclerosis or spinocerebellar degeneration.     ///    "In patients with neuro-Beh?et's disease, CSF-IAP levels and IAP% were elevated during the active stage, but remained normal levels during the inactive stage. "    ///    "In contrast, in patients with GBS or MFS, increased CSF-IAP levels without elevation of IAP% could be attributed largely to increased total CSF protein levels. "    ///    Assaying CSF-IAP could provide useful information about inflammatory or immunopathological events within the central nervous system.. 